
EC approves MSD’s pneumococcal 21-valent conjugate Capvaxive
MSD has received approval from the European Commission (EC) for Capvaxive, a pneumococcal 21-valent conjugate vaccine, to prevent invasive disease and pneumonia due to Streptococcus pneumoniae serotypes in people aged 18 years and over. The approval of …